期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

芳香化酶抑制剂治疗乳腺癌的研究进展及临床评价 被引量：2

Research and Development and Clinical Evaluation of Aromatase Inhibitors for the Treatment of Breast Cancer
暂未订购
导出
摘要 目的:介绍芳香化酶抑制剂的研究进展,评价其在乳腺癌治疗中的应用及临床价值。方法:查阅近期国内、外相关 文献进行整理、分析、总结。结果与结论:芳香化酶抑制剂用于绝经后晚期乳腺癌和早期乳腺癌术后辅助治疗的地位已经确 立。新一代芳香化酶抑制剂与早期芳香化酶抑制剂相比,其疗效和抑制作用均有显著差异,这与其临床疗效较好有一致性。 OBJECTIVE: To summarize the aspect of clinical evaluation and progresson aromatase inhibitors for the treatment of breast cancer. METHODS: To collect medical literatures in recent years at home and abroad. RESULTS & CONCLUSION: Position of Aromatase inhibitors for the treatment of late breast cancer and postoperative adjuvant treatment of early breast cancer is made certain. The new aromatase inhibitors have more advantages compared with the early ones.
作者 张艳华 汤致强
机构地区 北京大学临床肿瘤学院 中国医学科学院肿瘤医院
出处 《中国医院用药评价与分析》 2004年第1期9-11,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 芳香化酶抑制剂 乳腺癌 雌激素 流行病学 内分泌 aromatase inhibitors(AI) breast cancer estrogen clinical evaluation
分类号 R737.9 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献23

  • 1[1]Sondik EJ.Breast cancer trends:incidence,mortality and survival[J]. Cancer, 1994,74: 995.
  • 2[2]Jemal A,Thomas A,Murray T, et al. Cancer statistics,2002[J]. CA Cancer J Clin, 2002,52:23.
  • 3[3]Howe HL,Wingo PA,Thun MJ,et al. Annual reportto the nation on the status of cancer(1973 through 1988),featuring cancers with recent increasing trends[J].J Natl Cancer lnst, 2001,93:824.
  • 4[4]Theobald AJ.Management of advanced breast cancer with endocrine therapy:the role of the primary healthcare team[J].lnt J Clin Pract, 2000,54:665.
  • 5[5]Jaiyesimi IA, Buzdar AU,Decker DA.Use of tamoxifen for breast cancer: twenty-eight years later [J].J Clin Oncol, 1995,13:513.
  • 6[6]Masamura S, Adlercreutz H, Harvey H,et al. Aromatase inhibitor development for the treatment of breast cancer[J]. Breast Cancer Treat, 1995,33: 19.
  • 7闫敏,江泽飞,宋三泰.芳香化酶抑制剂治疗乳腺癌研究进展[J].国外医学（肿瘤学分册）,2003,30(2):125-128. 被引量：13
  • 8[8]Well SA, Santen RT, Lipton A, et al. Medical adrenalectomy with aminoglutet himide clinical studies in postmenopausal patients with metastatic breast carcino ma[J]. Ann Surg, 1978,187: 475.
  • 9[9]Lonning PE,Johannessen DC.Treatment of breast cancer with aromatase inhibitors[J].Drugs Today,1991,27:117.
  • 10[10]Goss PE, Powles TJ, Dowsett M,et al. Treatment of advanced postmenopausal breast cancer with the aromatase inhibitor,4-hydroxyandrostenedione:Phase Ⅱ report[J]. Cancer Res, 1986,46:4 823.

二级参考文献25

  • 1[1]Gale K E, Andersen J W, Tormey D C, et al. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase Ⅲ trial comparing aminoglutethimide to tamoxifen [J]. Cancer, 1994,73:354-361
  • 2[2]Thuerlimann B, Beretta K, Bacchi M, et al. First line fadrozole HCL(CGS 16949A) versus tamoxifen in postmenopausal patients with advanced breast cancer [J]. Ann Onco1,1996,7:471-479
  • 3[3]Gershanovich M, Chaudri H A, Campos D, et al. Letrozole, a new aromatase inhibitor: Randomized trial comparing 0.5 mg and 2.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Onco1,1998,9:639-645
  • 4[4]Kaufmann M, Bajetta E, Dirix L Y, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase Ⅲrandomised double-blind trial [J]. J Clin Oncol,2000,18:1399-1411
  • 5[5]Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase Ⅲ study of the International Letrozole Cancer Group [J]. J Clin Oncol,2001,19:2596-2606
  • 6Howell A, Buzdar A, Robertson J, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer [J]. Breast Cancer Res Treat, 1999,58(2):157-162.
  • 7Buzdar A, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase Ⅲ trials[J]. Cancer, 1998,83(6): 1142-1152.
  • 8Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate [J]. J Clin Oncol, 1998, 16(2):453-461.
  • 9Gershanovich M,Chaudri H, Campos D, et al. Letrozole, a new oral aromatase inhibitor:randomized trial comparing 2.5mg daily,0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Oncol, 1998,9(6): 639-645.
  • 10Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in advanced breast cancer: results of a phase Ⅲ randomized double-blind trial [J]. J Clin Oncol, 2000, 18(7): 1399-1411.

共引文献19

同被引文献20

  • 1杨静华.乳腺癌治疗药——芳香酶抑制剂类研究进展[J].中国新药杂志,1995,4(2):6-11. 被引量：6
  • 2[1]Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002.Cancer J Clin, 2002, 52( 1 ): 23.
  • 3[5]Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advance breast cancer. Breast Cancer Res Treat, 2002, 76(Supple): 37.
  • 4[6]Henderson C, Berry DA, Denetri GD, et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003, 21 (6):976.
  • 5[8]Talbot DC, Moiseyenko V, van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002, 86(9): 1367.
  • 6[9]O′ Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthra cycline-pretreated patients with advanced breast cancer: phase Ⅲ trial results. J Clin Oncol, 2002, 20(12): 2812.
  • 7[10]Venturini M, Durando A, Garrone O, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 2003, 97(5):1174.
  • 8[11]Biganzoil L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist, 2002, 7 (Suppl 6):29.
  • 9[14]The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal womem with early breast cancer: first results of the ATAC randomized trial. Lancet, 2002, 359: 2131.
  • 10[15]Nahboltz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen, a first line therapy for advanced breast cancer in postmenopausal women: results of a north American multicenter randomized trial. J Clin Oncol, 2000, 18(22): 3758.

引证文献2

二级引证文献7

中国医院用药评价与分析
2004年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部